Norway Antidiabetics Market, 2026-2033
The antidiabetics market in Norway is expected to reach a projected revenue of US$ 3,410.5 million by 2033. A compound annual growth rate of 11.1% is expected of Norway antidiabetics market from 2026 to 2033.
- Pharmaceuticals
- Metabolic Disorders Treatment
- antidiabetics market
- Metabolic Disorders Treatment
Revenue, 2025 (US$M)
$1,436.8
Estimate, 2026 (US$M)
$1,633.8
Forecast, 2033 (US$M)
$3,410.5
CAGR, 2026 - 2033
11.1%
Global Market
Related Markets
GVR research-powered AI
Ask Prism AI about the antidiabetics market
Get cited answers from GVR research on market growth, segments, regulations and forecasts.
- Source-linked answers
- Market-specific context
- Traceable figures
Norway antidiabetics market highlights
- The Norway antidiabetics market generated a revenue of USD 1,436.8 million in 2025 and is expected to reach USD 3,410.5 million by 2033.
- The Norway market is expected to grow at a CAGR of 11.1% from 2026 to 2033.
- In terms of segment, glp-1 receptor agonists was the largest revenue generating drug class in 2025.
- GLP-1 Receptor Agonists is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antidiabetics market data book summary
| Market revenue in 2025 | USD 1,436.8 million |
| Market revenue in 2033 | USD 3,410.5 million |
| Growth rate | 11.1% (CAGR from 2026 to 2033) |
| Largest segment | Glp-1 receptor agonists |
| Fastest growing segment | GLP-1 Receptor Agonists |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Insulin, GLP-1 Receptor Agonists, DPP- 4 Inhibitors, SGLT2 Inhibitors |
| Key market players worldwide | AstraZeneca PLC, Bayer AG, Takeda Pharmaceutical Co Ltd, Eli Lilly and Co, Boehringer Ingelheim, Bristol-Myers Squibb Co, Pfizer Inc, Johnson & Johnson, Merck & Co Inc, Novartis AG ADR |
Other key industry trends
- In terms of revenue, Norway accounted for 1.4% of the global antidiabetics market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, Germany antidiabetics market is projected to lead the regional market in terms of revenue in 2033.
- UK is the fastest growing regional market in Europe and is projected to reach USD 20,096.0 million by 2033.
No credit card required*
Publish Date: Apr 14, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antidiabetics Market
Antidiabetics market segmentation & scope
Antidiabetics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49,095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | www.takeda.com |
Norway antidiabetics market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Antidiabetics Market will help companies and investors design strategic landscapes.
Glp-1 Receptor Agonists was the largest segment with a revenue share of 58.31% in 2025.
Horizon Databook has segmented the Norway antidiabetics market based on insulin, glp-1 receptor agonists, dpp- 4 inhibitors, sglt2 inhibitors covering the revenue growth of each sub-segment from 2021 to 2033.
- Norway Antidiabetics Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
- Insulin
- GLP-1 Receptor Agonists
- DPP- 4 Inhibitors
- SGLT2 Inhibitors
- Others
- Norway Antidiabetics Market Diabetes Type Outlook (Revenue, USD Million , 2021-2033)
- Type 1
- Type 2
- Norway Antidiabetics Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Norway Antidiabetics Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
- Oral
- Subcutaneous
- Intravenous
Reasons to subscribe to antidiabetics market databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of antidiabetics market databook
- Our clientele includes a mix of antidiabetics market companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway antidiabetics market, including forecasts for subscribers. This country databook contains high-level insights into Norway antidiabetics market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Norway Antidiabetics Market, 2021-2033 (US$M)
Norway antidiabetics market statistics, by drug class, 2021-2033 (US$M)
